Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
MMW Fortschritte Der Medizin|November 21, 2002
[In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]Markolf Hanefeld
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2006
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus)Markolf Hanefeld
Atherosclerosis. Supplements|August 2, 2005
Introduction: new approaches to managing diabetic dyslipidaemiaMarkolf Hanefeld
Nature Clinical Practice. Cardiovascular Medicine|October 11, 2007
Is rosiglitazone associated with increased risk for cardiovascular events?Markolf Hanefeld
International Journal of Clinical Practice. Supplement|August 9, 2002
Postprandial hyperglycaemia: noxious effects on the vessel wallMarkolf Hanefeld
Expert Review of Endocrinology & Metabolism|February 14, 2019
Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variabilityMarkolf Hanefeld
Cardiovascular Diabetology|August 19, 2007
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetesMarkolf Hanefeld
Current Diabetes Reports|September 29, 2005
Prandial hyperglycemia: is it important to track and treat?Markolf Hanefeld, Frank Schaper
Expert Review of Cardiovascular Therapy|February 6, 2008
Acarbose: oral anti-diabetes drug with additional cardiovascular benefitsMarkolf Hanefeld, Frank Schaper
Herz|September 2, 2004
[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]Markolf Hanefeld, Frank Schaper
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
MMW Fortschritte Der Medizin|November 21, 2002
[In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]Markolf Hanefeld
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2006
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus)Markolf Hanefeld
Atherosclerosis. Supplements|August 2, 2005
Introduction: new approaches to managing diabetic dyslipidaemiaMarkolf Hanefeld
Nature Clinical Practice. Cardiovascular Medicine|October 11, 2007
Is rosiglitazone associated with increased risk for cardiovascular events?Markolf Hanefeld
International Journal of Clinical Practice. Supplement|August 9, 2002
Postprandial hyperglycaemia: noxious effects on the vessel wallMarkolf Hanefeld
Expert Review of Endocrinology & Metabolism|February 14, 2019
Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variabilityMarkolf Hanefeld
Cardiovascular Diabetology|August 19, 2007
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetesMarkolf Hanefeld
Current Diabetes Reports|September 29, 2005
Prandial hyperglycemia: is it important to track and treat?Markolf Hanefeld, Frank Schaper
Expert Review of Cardiovascular Therapy|February 6, 2008
Acarbose: oral anti-diabetes drug with additional cardiovascular benefitsMarkolf Hanefeld, Frank Schaper
Herz|September 2, 2004
[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]Markolf Hanefeld, Frank Schaper
Pageof 13